Acadia Pharmaceuticals (ACAD) Assets Average (2011 - 2026)

Acadia Pharmaceuticals' Assets Average history runs 16 years deep, the most recent figure standing at $1.6 billion for Q1 2026.

• In Q1 2026, Assets Average rose 36.61% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $1.6 billion (up 36.61% YoY), while the FY2025 annual figure was $1.4 billion, up 42.09% from the prior year.
• Assets Average was $1.6 billion for Q1 2026 at Acadia Pharmaceuticals, up from $1.4 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.6 billion in Q1 2026 to a low of $595.2 million in Q4 2022.
• Historically, Assets Average has averaged $908.6 million across 5 years, with a median of $802.0 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Assets Average slipped 16.4% in 2022, then jumped 56.69% in 2024.
• A 5-year view of Assets Average shows it stood at $595.2 million in 2022, then grew by 16.06% to $690.7 million in 2023, then surged by 56.69% to $1.1 billion in 2024, then surged by 33.74% to $1.4 billion in 2025, then rose by 9.48% to $1.6 billion in 2026.
• The last three Assets Average figures came in at $1.6 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.